Efficacy, Tolerability, and Safety of Fluoxetine for Panic Disorder in Adults: A Review

Mechanisms of change in cognitive behavioral therapy for panic disorder: the unique effects of self-efficacy and anxiety sensitivity

10.1016/j.brat.2013.09.001 · doi-reference

Self-efficacy: toward a unifying theory of behavioral change

10.1037/0033-295x.84.2.191 · doi-reference

Personalized virtual reality exposure for panic disorder and agoraphobia: a preliminary neurophysiological study

10.1016/j.comppsych.2023.152447 · doi-reference

Pilot randomized trial of self-guided virtual reality exposure therapy for social anxiety disorder

10.1016/j.brat.2021.103984 · doi-reference

Innovative virtual reality exposure therapy for anxiety and posttraumatic stress disorder: a meta-analysis of randomised controlled trials

10.7189/jogh.16.04090 · doi-reference

Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia

10.1111/j.1600-0447.2008.01157.x · doi-reference

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants

10.1002/cpt.2903 · doi-reference

Antidepressant withdrawal and rebound phenomena

10.3238/arztebl.2019.0355 · doi-reference

Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis

10.1371/journal.pone.0178617 · doi-reference

Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder

10.4088/jcp.v60n0505 · doi-reference

The assessment of anxiety states by rating

10.1111/j.2044-8341.1959.tb00467.x · doi-reference

Mirtazapine versus fluoxetine in the treatment of panic disorder

10.1590/s0100-879x2001001000010 · doi-reference

Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group

10.1007/pl00014164 · doi-reference

Pharmacological treatments in panic disorder in adults: a network meta-analysis

10.1002/14651858.cd012729.pub3 · doi-reference

Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials

10.1136/bmj-2021-066084 · doi-reference

Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: a systematic review and network meta-analysis

10.1016/j.ajp.2021.102664 · doi-reference

Newer antidepressants and panic disorder: a meta-analysis

10.1097/yic.0b013e32835a5d2e · doi-reference

PEGylated chitosan nanoparticles of fluoxetine enhance cognitive performance and hippocampal brain derived neurotrophic factor levels in a rat model of local demyelination

10.1016/j.exger.2024.112533 · doi-reference

Potentiation of brain bioavailability using thermoreversible cubosomal formulation

10.1021/acs.molpharmaceut.4c00085 · doi-reference

Hydrochloride salt co-crystals: preparation, characterization and physicochemical studies

10.3109/10837450.2012.696270 · doi-reference

Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and clinical determinants of fluoxetine-norfluoxetine pharmacokinetics in real-world clinical conditions

10.3390/pharmaceutics18010041 · doi-reference

Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids

10.1021/ja048114o · doi-reference

Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents

10.1007/s00228-025-03893-9 · doi-reference

An open trial of fluoxetine in the treatment of panic attacks

10.1097/00004714-198710000-00007 · doi-reference

Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial

10.1192/bjp.179.6.514 · doi-reference

Fluoxetine: a review on evidence based medicine

10.1186/1475-2832-3-2 · doi-reference

Pharmacological therapy in panic disorder: current guidelines and novel drugs discovery for treatment-resistant patient

10.9758/cpn.2019.17.2.145 · doi-reference

Is it possible to prevent relapse in panic disorder?

10.1080/14737175.2023.2229955 · doi-reference

Pharmacotherapy of panic disorder

10.2147/ndt.s1224 · doi-reference

Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group

10.1176/ajp.155.11.1570 · doi-reference

Antidepressants versus placebo for panic disorder in adults

10.1002/14651858.cd010676.pub2 · doi-reference